查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2029265

周邊T細胞淋巴瘤（PTCL）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Peripheral T-Cell Lymphoma (PTCL) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 153 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國PTCL市場預計將從2,100萬美元成長到3,200萬美元，反映出市場溫和擴張。
  • 市場成長受以下因素驅動：
  • 採用標靶治療和抗體藥物複合體
  • 增加移植和二線治療策略的使用
  • 雖然患者人數不多，但昂貴的治療方法和密集的治療方法支撐了市場規模。
  • 表觀遺傳療法和新型免疫腫瘤藥物的持續創新有望塑造未來的市場動態。
  • 未來的成長取決於開發針對復發或難治性疾病患者的有效治療方法，以及提高存活率。

周邊T細胞淋巴瘤（PTCL）概述

周邊T細胞淋巴瘤（PTCL）是一組罕見、異質性強且高度侵襲性的成熟T細胞和自然殺手（NK）細胞腫瘤，約佔所有非何傑金氏淋巴瘤的10-15%。此疾病包含幾種生物特性不同的亞型，其中最常見的是PTCL-NOS（非其他類型的周邊T細胞淋巴瘤）、血管免疫母細胞性T細胞淋巴瘤（AITL）和間變性大細胞淋巴瘤（ALCL）。這些亞型分別由表觀遺傳學改變、T細胞受體訊號傳導異常和致癌性突變所引起。

臨床上，周邊T細胞淋巴瘤（PTCL）的特徵是疾病進展迅速、淋巴結廣泛腫大、全身性B細胞症狀（發燒、盜汗、體重減輕）以及常見的結外病變，包括皮膚、骨髓和肝臟受累。與B細胞淋巴瘤相比，此疾病進展通常較快，預後較差。

傳統上，以CHOP方案為基礎的第一線化療療效不佳，且由於內源性化療抗藥性，復發率較高。隨後，治療模式不斷發展，特別是隨著分子標靶治療的引入。對於CD30陽性亞型（尤其是間變性大細胞淋巴瘤），布倫妥昔單抗合併化療（BV-CHP）是建議的第一線治療方案。

對於合格的已緩解患者，自體周邊血幹細胞移植（ASCT）通常用於維持治療。對於復發或難治性病例，則採用新型分子標靶療法，包括組蛋白去乙醯化酶（HDAC）抑制劑和抗葉酸類藥物（如普拉曲沙）。儘管取得了這些進展，但治療效果仍然有限，凸顯了對更有效、更持久的治療方法的迫切需求。

主要亮點

  • 在法國，預計新診斷的 PTCL 病例數將從 1448 例增加到 1981 例，這表明該疾病對患者群體帶來的負擔日益加重。
  • PTCL 仍然是一種罕見疾病，但它是淋巴瘤的一種高度侵襲性亞型，與 B 細胞淋巴瘤相比，其預後較差。
  • 由於對傳統化療有其固有抗藥性，復發率居高不下。
  • 治療模式正在轉向標靶治療（例如，brentoximab vedotin）和精準醫療方法。
  • 復發/難治性 PTCL 的治療和長期疾病控制方面存在著巨大的未滿足需求。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Xenothera SAS
  • Dizal Pharmaceuticals
  • Chipscreen Biosciences, Ltd.
  • Boryung Pharmaceutical Co., Ltd
  • SecuraBio
  • Acrotech Biopharma Inc.
  • Boston Immune Technologies and Therapeutics
  • Corvus Pharmaceuticals, Inc.
  • SciTech Development, Inc.
  • Aileron Therapeutics, Inc.
  • AstraZeneca
  • Kymera Therapeutics, Inc.
  • Bio-Path Holdings, Inc.
  • Pfizer

目錄

第1章：主要調查結果和分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Peripheral T-Cell Lymphoma (PTCL) Market Outlook

Thelansis's "Peripheral T-Cell Lymphoma (PTCL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Peripheral T-Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Peripheral T-Cell Lymphoma (PTCL) Overview

Peripheral T-cell lymphoma (PTCL) represents a rare, heterogeneous, and highly aggressive group of mature T-cell and natural killer (NK)-cell neoplasms, accounting for approximately 10-15% of all non-Hodgkin lymphomas. The disease comprises multiple biologically distinct subtypes, most commonly PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL), each driven by epigenetic alterations, aberrant T-cell receptor signaling, and oncogenic mutations.

Clinically, PTCL is characterized by rapid disease progression, presenting with generalized lymphadenopathy, systemic B symptoms (fever, night sweats, weight loss), and frequent extranodal involvement, including the skin, bone marrow, and liver. The disease course is typically aggressive, with poor prognosis compared to B-cell lymphomas.

Historically, frontline treatment with CHOP-based chemotherapy resulted in suboptimal outcomes and high relapse rates due to intrinsic chemoresistance. The treatment paradigm has since evolved, particularly with the incorporation of targeted therapies. For CD30-positive subtypes (notably ALCL), the combination of brentuximab vedotin with chemotherapy (BV-CHP) has become a preferred frontline regimen.

Consolidation with autologous stem cell transplantation (ASCT) is commonly pursued in eligible patients achieving remission. In the relapsed/refractory setting, treatment relies on novel targeted agents, including histone deacetylase (HDAC) inhibitors and antifolate therapies such as pralatrexate. Despite these advances, outcomes remain limited, underscoring a significant unmet need for more effective and durable therapies.

Key Highlights

  • In France, diagnosed incident PTCL cases are projected to increase from 1,448 to 1,981, indicating a rising disease burden.
  • PTCL remains a rare but highly aggressive lymphoma subtype with poor prognosis compared to B-cell lymphomas.
  • High relapse rates persist due to intrinsic resistance to conventional chemotherapy.
  • Treatment paradigm is shifting toward targeted therapies (e.g., brentuximab vedotin) and precision medicine approaches.
  • Significant unmet need exists in relapsed/refractory PTCL and long-term disease control.

Market Overview

  • The France PTCL market is projected to grow from $21M to $32M, reflecting moderate market expansion.
  • Market growth is driven by:
  • Adoption of targeted therapies and antibody-drug conjugates
  • Increasing use of transplant and second-line treatment strategies
  • Despite low patient numbers, market value is supported by high-cost therapies and intensive treatment approaches.
  • Continued innovation in epigenetic therapies and novel immuno-oncology agents is expected to shape future market dynamics.
  • Future growth will depend on effective therapies for relapsed/refractory patients and improved survival outcomes.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Xenothera SAS
  • Dizal Pharmaceuticals
  • Chipscreen Biosciences, Ltd.
  • Boryung Pharmaceutical Co., Ltd
  • SecuraBio
  • Acrotech Biopharma Inc.
  • Boston Immune Technologies and Therapeutics
  • Corvus Pharmaceuticals, Inc.
  • SciTech Development, Inc.
  • Aileron Therapeutics, Inc.
  • AstraZeneca
  • Kymera Therapeutics, Inc.
  • Bio-Path Holdings, Inc.
  • Pfizer

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)